Skip to Main Content

Advertisement

Skip Nav Destination

Abstract 4252: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models

Cancer Res (2022) 82 (12_Supplement): 4252.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal